Floatz logo

ETOPOSIDE

HER2-negative Breast Cancer Brain Metastases

Beijing 302 HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the HER2-negative Breast Cancer Brain Metastases cohort.

Asset / SponsorPhaseRating
Carboplatin
Beijing 302 Hospital
Phase 2CCC
Adebrelimab
Beijing 302 Hospital
Phase 2CCC
Rivoceranib
Beijing 302 Hospital
Phase 2CCC

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →